Full-Time
Manager Enterprise Sales
GE Healthcare
1-10 employees
Imaging, monitoring, and healthcare IT solutions
No salary listed
Chennai, Tamil Nadu, India
In Person
Relocation assistance is provided.
Bachelor's, Master's, MBA
 Sales & Account Management (1) |
|---|
Get referred to GE Healthcare
See people who can refer or advise you
- A Bachelor's degree in Pharmacy, Life Sciences, or a related field is required.
- At least 12 years of relevant experience in sales, account management, healthcare diagnostics, or pharmaceuticals is required.
- Strong product knowledge and proven experience in enterprise account management and planning are required.
- Five to six years of experience working with or leading cross-functional teams is required.
- Experience collaborating and coordinating with internal and external stakeholders while preparing rate contracts with enterprise accounts is required.
- Strong influencing, interpersonal, and stakeholder management skills are required.
- Strong analytical thinking and problem-solving abilities are required.
- Excellent presentation skills and the ability to engage and influence senior stakeholders are required.
- Represent One GE HealthCare – Pharmaceutical Diagnostics across multi-year enterprise engagements, strategic partnerships, and cross-functional initiatives.
- Own executive-level issue resolution and ensure high customer satisfaction across key accounts.
- Deliver operating plan commitments including revenue, growth, margin, cash, and market development objectives.
- Build and sustain trust-based relationships with senior stakeholders, including C-suite leaders, clinical heads, Pharmacy, Procurement, and Research teams.
- Lead enterprise account planning, including account-specific growth strategies, stakeholder mapping and influence networks, and long-term partnership development.
- Drive joint value planning with customers to define shared clinical, operational, and financial goals and key performance indicators.
- Collaborate with Product and Marketing teams to drive regional engagement initiatives, including key opinion leader development and segmentation-based customer engagement.
- Ensure compliance with GE HealthCare policies, procedures, and operating mechanisms.
- Collaborate with internal and external stakeholders to develop and finalize rate contracts with enterprise accounts, ensuring timely closure.
- Identify expressed and latent customer needs across oncology, neurology, cardiology, and molecular imaging.
- Lead the development of high-impact clinical, scientific, and commercial proposals that articulate Pharmaceutical Diagnostics value propositions.
- Collaborate with Medical Affairs, Legal, Research and Development, Regulatory, Quality, Supply Chain, and Finance to align enterprise account requirements.
- Strengthen product knowledge to enhance clinical differentiation and drive account potential mapping.
- Develop and execute annual engagement plans to drive customer mindshare and revenue growth.
- An MBA in Sales and Marketing or a relevant master's degree is preferred.
- Demonstrated success in managing large, complex accounts and closing strategic deals is preferred.
- Strong communication skills in English and local languages are preferred.
- Ability and willingness to travel extensively across assigned geographies is preferred.
GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.
Company Size
1-10
Company Stage
IPO
Headquarters
Chicago, Illinois
Founded
1892
Get referred to GE Healthcare
See people who can refer or advise you
Simplify's Take
What believers are saying
- Photonova Spectra won CE Mark on August 31, 2026, opening Europe sales.
- Q2 2026 orders rose 11.1%, with 1.15x book-to-bill and record backlog.
- Vivid cardiovascular ultrasound and ABUS breast screening launches broaden 2026 revenue opportunities.
What critics are saying
- Patient Care Solutions revenue fell 13.5% in Q2 2026; management is reviewing a sale.
- Jay Saccaro left in August 2026; William Grogan starts September 14, 2026.
- If PCS recovery slips into 2027, GE HealthCare becomes a slower-growth imaging vendor.
What makes GE Healthcare unique
- Photonova Spectra’s Deep Silicon CT differentiates GE HealthCare with photon-counting imaging.
- GE HealthCare spans imaging, pharma diagnostics, ultrasound, and monitoring across hospital workflows.
- The July 2026 backlog of $23.9 billion reflects sticky installed-base demand and services.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Tuition Reimbursement
Relocation Assistance
Company News
GE HealthCare has received CE mark approval for its Photonova Spectra photon-counting computed tomography system, enabling commercial sales in markets recognising CE marking. The clearance follows US Food and Drug Administration approval and Japanese regulatory clearance in March 2026. The system uses GE HealthCare's Deep Silicon detector technology to deliver ultra-high definition spectral and spatial imaging. It processes data volumes up to 50 times greater than conventional CT systems, utilising Nvidia's accelerated computing platform. Clinical collaborations are underway at UZ Brussel in Belgium and Rigshospitalet in Denmark to evaluate the system across cardiology, neurology, oncology and musculoskeletal imaging. The CE mark follows more than $5 billion in innovation investment by GE HealthCare.
Vertex Pharmaceuticals has emerged as a standout S&P 500 stock, according to StockStory's analysis. The company, which focuses on developing transformative medicines for serious diseases including cystic fibrosis and sickle cell disease, boasts a market capitalisation of $137.3 billion. Meanwhile, StockStory recommends avoiding two large-cap stocks. GE HealthCare, spun off from General Electric in 2023, faces concerns over stagnant organic revenue growth and declining operating margins. The medical equipment provider has a market cap of $32.4 billion. Wells Fargo also made the avoid list. The diversified financial services company, with a $262.2 billion market cap, has seen its net interest margin shrink by 33.6 basis points over two years, suggesting increased competition or declining loan profitability.
GE HealthCare has introduced three new cardiovascular ultrasound systems to its Vivid portfolio: Vivid Explorer 1, Vivid Advanced 1, and Vivid Focus 1. The systems were unveiled at the European Society of Cardiology Congress 2026 in Munich, Germany. Each system targets different clinical settings whilst sharing a common technology foundation with the ultra-premium Vivid Pioneer. Vivid Explorer is designed for high-volume echo labs, Vivid Advanced for mid-size hospitals and cardiology practices, and Vivid Focus for everyday cardiac imaging. All three systems use cSound imaging technology and include AI-enabled automation tools to streamline echo workflows. The systems have received CE Mark approval but are awaiting US FDA 510(k) clearance and are not yet available for sale in the United States.
GE HealthCare has launched Invenia ABUS Prime and ABUS StreamVue, expanding its breast imaging portfolio with solutions for supplemental screening in women with dense breasts. The Invenia ABUS Prime system has been installed at BeSound in Los Angeles, marking one of the first US installations. ABUS StreamVue is a browser-based reading solution enabling remote exam review across imaging networks. The system received FDA 510(k) clearance and CE Marking. Studies show 40% of women have dense breasts, carrying four to six times higher breast cancer risk. Research indicates mammography may miss one-third of cancers in dense breasts. Invenia ABUS Prime features AI-enabled tools including Scan Quality Assessment and can increase scan speed by up to 40%. The AI Assistant has demonstrated a 33% reduction in reading time.
GE HealthCare Technologies reported second-quarter results with orders rising 11% year-over-year and backlog reaching a record $23.9 billion. Revenue grew 3.5% organically to $5.3 billion, driven by Advanced Imaging Solutions and Pharmaceutical Diagnostics, which posted organic growth of 5% and 14.6% respectively. Patient Care Solutions remained weak, with revenue falling 13.5% due to component shortages and fulfilment problems. Management is reviewing strategic options for the segment, including a potential sale. The company maintained its full-year outlook of 3–4% organic sales growth, adjusted earnings per share of $4.80–$5.00, and approximately $1.6 billion in free cash flow. CFO Jay Saccaro is departing, with George Newcomb serving as interim CFO.